Merck's MK-1403 bioavailability trial listed as completed in registry update
A Phase 1 crossover study testing MK-1403 tablet formulations in healthy volunteers is recorded as completed, per ClinicalTrials.gov.
Merck's main registry update this week concerns a single early-stage trial for MK-1403, an investigational treatment aimed at atherosclerotic cardiovascular disease.
- MK-1403 (NCT07677163), a Phase 1 trial comparing two oral tablet formulations in healthy adults, is listed with an actual start date of 2026-08-14 and a primary completion date of 2026-10-05, with overall status marked completed.1 The study is titled "A Clinical Study to Evaluate the Relative Bioavailability of MK-1403 Formulations Administered to Healthy Adult Participants."1
- The drug is being developed to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).1
- The trial enrolled 15 participants in a randomized crossover design, phase 1, with a primary purpose of basic science.1
- Primary outcomes included the number of participants who experience an adverse event, and pharmacokinetic measures such as area under the concentration-time curve and maximum plasma concentration of MK-1403.1
- The study was conducted at one site, QPS-MRA, LLC in South Miami, Florida, United States.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.